AstraZeneca's Lynparza Slows Advanced Breast Cancer Progression

Women in the study had metastatic breast cancer classified as hormone receptor-positive or triple negative and had undergone prior chemotherapy.

- 

WOMEN WITH advanced breast cancer who carry specific genetic mutations experienced double the response rate and delayed disease progression when treated with AstraZeneca's Lynparza compared with standard chemotherapy, according to data from a late-stage trial.

In the study of 302 patients with inherited mutations of the BRCA1 or BRCA2 genes, about 60 per cent who received the oral treatment Lynparza experienced significant tumour shrinkage compared with 29 per cent who got chemotherapy. Nine per cent of Lynparza patients had a complete response versus two per cent on chemotherapy.

Median time to disease worsening was seven months with Lynparza versus 4.2 months for chemotherapy, a statistically significant 42 per cent reduction in progression risk.